Q1 Earnings Forecast for MNMD Issued By Leerink Partnrs

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for Mind Medicine (MindMed) in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings of ($0.35) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

Mind Medicine (MindMed) (NASDAQ:MNMD) last released its earnings results on Thursday, November 7th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. During the same period last year, the company earned ($0.53) EPS.

Other equities research analysts have also issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of Mind Medicine (MindMed) in a research note on Monday, November 11th. Leerink Partners began coverage on Mind Medicine (MindMed) in a report on Monday, October 14th. They issued an “outperform” rating and a $20.00 target price on the stock. Evercore ISI started coverage on Mind Medicine (MindMed) in a research note on Tuesday. They issued an “outperform” rating and a $23.00 price objective on the stock. Chardan Capital started coverage on Mind Medicine (MindMed) in a research note on Friday, December 20th. They issued a “buy” rating and a $20.00 target price for the company. Finally, Oppenheimer reissued an “outperform” rating and set a $20.00 price objective on shares of Mind Medicine (MindMed) in a report on Tuesday, December 17th. Ten investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $26.33.

Mind Medicine (MindMed) Stock Down 2.6 %

Shares of MNMD stock opened at $7.13 on Thursday. Mind Medicine has a one year low of $3.82 and a one year high of $12.22. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00. The stock has a fifty day moving average price of $7.28 and a 200 day moving average price of $6.94. The stock has a market cap of $522.84 million, a P/E ratio of -3.15 and a beta of 2.60.

Hedge Funds Weigh In On Mind Medicine (MindMed)

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MNMD. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Mind Medicine (MindMed) during the 3rd quarter worth about $58,000. Sanctuary Advisors LLC acquired a new position in Mind Medicine (MindMed) during the third quarter valued at approximately $91,000. Foundations Investment Advisors LLC bought a new position in Mind Medicine (MindMed) in the fourth quarter valued at approximately $91,000. Stoneridge Investment Partners LLC bought a new position in Mind Medicine (MindMed) in the third quarter valued at approximately $93,000. Finally, SG Americas Securities LLC acquired a new position in shares of Mind Medicine (MindMed) during the 3rd quarter worth approximately $93,000. 27.91% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Mind Medicine (MindMed)

In other Mind Medicine (MindMed) news, CEO Robert Barrow sold 19,106 shares of the stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $7.43, for a total value of $141,957.58. Following the completion of the sale, the chief executive officer now directly owns 526,666 shares in the company, valued at $3,913,128.38. This represents a 3.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dan Karlin sold 6,643 shares of Mind Medicine (MindMed) stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $7.43, for a total value of $49,357.49. Following the transaction, the insider now owns 338,013 shares in the company, valued at $2,511,436.59. This trade represents a 1.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,022 shares of company stock worth $208,203 over the last ninety days. Company insiders own 2.26% of the company’s stock.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.